Dopaminergic intracellular signal integrating proteins: Relevance to schizophrenia

Dialogues in Clinical Neuroscience

Volumn 8, Issue 1, 2006, Pages 95-100

  Souza, Bruno R ^a   Souza, Renan P ^a   Rosa, Daniela V F ^a   Guimarães, Melissa M ^a   Correa, Humberto ^a   Romano Silva, Marco A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Dopamine receptor; G protein coupled receptor; Schizophrenia; Second messenger

Indexed keywords

CALMODULIN; DOPAMINE RECEPTOR; FILAMIN A; G PROTEIN COUPLED RECEPTOR; LAMOTRIGINE; LITHIUM; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE B; PROTEIN NCS 1; PROTEINASE ACTIVATED RECEPTOR 4; SIGNAL PEPTIDE; SPINOPHILIN; UNCLASSIFIED DRUG; VALPROIC ACID;

BRAIN REGION; CALCIUM SIGNALING; DOPAMINERGIC ACTIVITY; GENE EXPRESSION; HUMAN; NONHUMAN; REVIEW; SCHIZOPHRENIA; THYMOMA; VIRUS ONCOGENE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CALMODULIN; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICROFILAMENT PROTEINS; NEURONAL CALCIUM-SENSOR PROTEINS; NEUROPEPTIDES; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 33646126709     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res. 2004;24:165-205.
2. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov. 2002;1:808-820.
3. Lee SP, So CH, Rashid AJ, Varghese G, et al. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem. 2004;279:35671-35678.
4. O'Dowd BF, Ji X, Alijaniaram M, et al. Dopamine receptor oligomerization visualized in living cells. J Biol Chem. 2005;280:37225-37235.
5. So CH, Varghese G, Curley KJ, et al. D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol. 2005;68:568-578.
6. Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS. Dopamine receptor interacting proteins: the Ca(2+) connection in dopamine signaling. Trends Pharmacol Sci. 2003;24:486-492.
7. Lidow MS. Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res Brain Res Rev. 2003;43:70-84.
8. Hillion J, Canals M, Torvinen M, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors, J Biol Chem. 2002;277:18091-18097.
9. Agnati LF, Ferre S, Burioni R, et al. Existence and theoretical aspects of homomeric and heteromeric dopamine receptor complexes and their relevance for neurological diseases. Neuromolecular Med. 2005;7:61-78.
10. Torvinen M, Marcellino D, Canals M, et al. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol. 2005;67:400-407.
11. Albert KA, Hemmings HC Jr, Adamo AI, et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry. 2002;59:705-712.
12. Hernandez-Lopez S, Tkatch T, Perez-Garci E, et al. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci. 2000;20:8987-8995.
13. Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic PS, Lidow MS. Upregulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc Natl Acad Sci U S A. 2003;100:313-317
14. Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch Gen Psychiatry. 2003;60:311-319.
15. Bai J, He F, Novikova SI, et al. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry. 2004;56:427-440.
16. Kabbani N, Negyessy L, Lin R, Goldman-Rakic P, Levenson R. Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor. J Neurosci. 2002;22:8476-8486.
17. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997;17:8147-8155.
18. Negyessy L, Goldman-Rakic PS. Subcellular localization of the dopamine D2 receptor and coexistence with the calcium-binding protein neuronal calcium sensor-1 in the primate prefrontal cortex. J Comp Neurol. 2005;488:464-475.
19. Park SK, Nguyen MD, Fischer A, et al. Par-4 links dopamine signaling and depression. Cell. 2005;122:275-287.
20. De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science. 1998;279:227-230.
21. Xia Z, Storm DR. The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci. 2005;6:267-276.
22. Chowdari KV, Mirnics K, Semwal P, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet. 2002;11:1373-1380.
23. Williams NM, Preece A, Spurlock G, et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry. 2004;55:192-195.
24. Morris DW, Rodgers A, McGhee KA, et al. Confirming RGS4 as a susceptibility gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2004;125:50-53.
25. Zhang F, St Clair D, Liu X, et al. Association analysis of the RGS4 gene in Han Chinese and Scottish populations with schizophrenia. Genes Brain Behav. 2005;4:444-448.
26. Cordeiro Q, Talkowski ME, Chowdari KV, Wood J, Nimgaonkar V, Vallada H. Association and linkage analysis of RGS4 polymorphisms with schizophrenia and bipolar disorder in Brazil. Genes Brain Behav. 2005;4:45-50.
27. Sobell JL, Richard C, Wirshing DA, Heston LL. Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians. Am J Med Genet B Neuropsychiatr Genet. 2005;139:23-27.
28. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001;6:293-301.
29. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003;73:34-48.
30. Popov SG, Krishna UM, Falck JR, Wilkie TM. Ca2+/calmodulin reverses phosphatidylinositol 3,4,5-trisphosphate-dependent inhibition of regulators of G protein-signaling GTPase-activating protein activity. J Biol Chem. 2000;275:18962-18968.
31. Ishii M, Kurachi Y. Physiological actions of regulators of G-protein signaling (RGS). Proteins Life Sci. 2003;74, 163-171
32. Ishii M, Inanobe A, Kurachi Y. PIP3 inhibition of RGS protein and its reversal by Ca2+/calmodulin mediate voltage-dependent control of the G protein cycle in a cardiac K+ channel. Proc Natl Acad Sci U S A. 2002;99:4325-4330.
33. Ishii M, Inanobe A, Fujita S, Makino Y, Hosoya Y, Kurachi Y. Ca2+ elevation evoked by membrane depolarization regulates G protein cycle via RGS proteins in the heart. Circ Res. 2001;89:1045-1050.
34. Kurachi, Y, Ishii, M. Cell signal control of the G protein-gated potassium channel and its subcellular localization. J Physiol (Cambridge, UK). 2004;554, 285-294
35. Ishii M, Fujita S, Yamada M, Hosaka Y, Kurachi Y. Phosphatidylinositol 3,4,5-trisphosphate and Ca2+/calmodulin competitively bind to the regulators of G-protein-signalling (RGS) domain of RGS4 and reciprocally regulate its action. Biochem J. 2005;385:65-73.
36. Grillet N, Pattyn A, Contet C, Kieffer BL, Goridis C, Brunet JF. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol. 2005;25:4221-8.
37. Taymans JM, Kia HK, Claes R, Cruz C, Leysen J, Langlois X. Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. Eur J Neurosci. 2004;19:2249-2260.
38. Taymans JM, Leysen JE, Langlois X. Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem. 2003;84:1118-1127.
39. Wang Q, Zhao J, Brady AE, Feng J, et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science. 2004;304:1940-1944.
40. Jeanneteau F, Diaz J, Sokoloff P, Griffon N. Interactions of GIPC with dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-coupled receptors. Mol Biol Cell. 2004;15:696-705.
41. Jeanneteau F, Guillin O, Diaz J, Griffon N, Sokoloff P. GIPC recruits GAIP (RGS19) to attenuate dopamine D2 receptor signaling. Mol Biol Cell. 2004;15:4926-4937.
42. Allen PB, Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci U S A. 1997;94:9956-9961
43. Smith FD, Oxford GS, Milgram SL. Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J Biol Chem. 1999;274:19894-19900.
44. Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ. Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines. Am J Psychiatry. 2004;161:1848-1855.
45. Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V, Meador-Woodruff JH. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry. 2005;162:1859-1871.
46. Li M, Bermak JC, Wang ZW, Zhou QY. Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol. 2000;57:446-452.
47. Li M, Li C, Weingarten P, Bunzow JR, Grandy DK, Zhou QY. Association of dopamine D(3) receptors with actin-binding protein 280 (ABP-280). Biochem Pharmacol. 2002;63:859-863.
48. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987;84:5034-5037.
49. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991;254:274-277.
50. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991;201:475-481.
51. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA. 1991;88:4171-4175.
52. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381-395.
53. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376:599-602.
54. Franke, TF, Yang S, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727-736.
55. Cross DA, Aless DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378, 785-789.
56. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93:8455-8459
57. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6:1664-1668.
58. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 2001;280:720-725.
59. Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun. 2002;290:967-72.
60. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res. 2005;137:193-201.
61. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734-36741.
62. Yang SD, Yu JS, Lee TT, Yang CC, Ni MH, Yang YY. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. J Cell Biochem. 1995;59:108-116.
63. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res. 2001;52:101-105.
64. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry. 2000;157:831-833.
65. Beasley C, Cotter D, Khan N, et al. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett. 2001;302:117-120.
66. Nadri C, Dean B, Scarr E, Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res. 2004;71:377-382.
67. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004;36:131-137.
68. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101:5099-5104.
69. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122:261-273.